Retatrutide is classified as a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors), making it more effective for body fat mass reduction than its predecessor Semaglutide by targeting further receptors
The American Journal of Medicine
Any treatment aimed to manage diabetes or support weight loss works only along with a proper diet and exercise
Bottom-up Approach and Top-down Approach The total market was split into several segments and subsegments after arriving at the overall market size from the estimation process
The findings were compelling, tirzepatide not only achieved greater reductions in HbA1c but also delivered significant body weight loss, all while showing a lower incidence of hypoglycemia at the 52-week mark
Before and after images reflect real results from real patients, although individual results may vary